{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:33Z","timestamp":1792097073714,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaccas.2026.109561","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:24:44Z","timestamp":1786188284000},"page":"109561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ApoC-III Antisense Oligonucleotide Therapy Used in Glycogen Storage Disease Type 1a"],"prefix":"10.1016","volume":"31","author":[{"given":"Joseph","family":"Burns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Reid","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-2401","authenticated-orcid":false,"given":"Justin P.","family":"Zachariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2026.109561_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacl.2012.08.005","article-title":"Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism","volume":"6","author":"Sever","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jaccas.2026.109561_bib2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaccas.2026.109561_bib3","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1007\/BF02680007","article-title":"Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I)","volume":"161","author":"Rake","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaccas.2026.109561_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2251-6581-12-25","article-title":"Glycogen Storage Disease type 1a\u2013a secondary cause for hyperlipidemia: report of five cases","volume":"12","author":"Carvalho","year":"2013","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.jaccas.2026.109561_bib5","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1097\/MS9.0000000000003768","article-title":"Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS)","volume":"87","author":"Khan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jaccas.2026.109561_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-025-01295-x","article-title":"Novel therapeutics for familial chylomicronemia syndrome","volume":"27","author":"Izar","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jaccas.2026.109561_bib7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaccas.2026.109561_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jaccas.2026.109561_bib9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1203\/PDR.0b013e31816c9013","article-title":"Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a","volume":"63","author":"Bandsma","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jaccas.2026.109561_bib10","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926027221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926027221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:41Z","timestamp":1792093781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926027221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666084926027221"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109561","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ApoC-III Antisense Oligonucleotide Therapy Used in Glycogen Storage Disease Type 1a","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"109561"}}